Choose Your Language:Chinese (Simplified) Chinese (Traditional) Danish Dutch English French German Italian Portuguese Spanish
January 8, 2021 — Since 2019, our small but mighty and growing community has seen three FDA-approved therapies. At TSF, we’re huge advocates for shared-decision making between patients and their physicians, especially when it comes to deciding what treatment(s) to opt for.
The Sumaira Foundation for NMO is pleased to announce its launch the first-of-its-kind
Our intention in laying out these new and available therapies side-by-side is to empower the patient community to discuss their treatment options with their doctors to make informed decisions about their best paths forward.
TSF works with all three pharmaceutical companies equally with an unbiased and objective lens.
Special thanks to Dr. Michael Levy (subject-matter expert), Andrea Sydney (volunteer project manager), and 3Dcubed (animator) for their support in bringing this chart to fruition. Thank you, Genentech, a Member of the Roche Group for your generous support.
Cheers to innovation for NMOSD patients everywhere!